AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent B Acute Lymphoblastic Leukemia

CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: cladribine, cytarabine,venetoclax Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Tรผbingen๐Ÿ“ Ulm University Hospital Tuebingen ยท Tests: Tafasitamab MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site๐Ÿ“ Amman King Hussein Cancer Center ยท Tests: MB-CART19.1 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia NCT07133997Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT05442515Phase 1, Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia NCT07105579Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: BITE and DLI A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT04546399Phase 2227 sites๐Ÿ“ Birmingham๐Ÿ“ Mobile๐Ÿ“ Anchorage National Cancer Institute (NCI) ยท Tests: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bonโ€ฆ NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites๐Ÿ“ Ankara๐Ÿ“ Ankara๐Ÿ“ Ankara Health Institutes of Turkey ยท Tests: Talikabtagene Autoleucel Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies NCT05705570Phase 11 site๐Ÿ“ Sรฃo Paulo Nelson Hamerschlak ยท Tests: Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on dayโ€ฆ HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) NCT01853631Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide Study of Out of Specification for Tisagenlecleucel NCT04094311Phase 355 sites๐Ÿ“ Hamilton๐Ÿ“ Ottawa๐Ÿ“ Toronto Novartis Pharmaceuticals ยท Tests: CTL019 CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL NCT06445803Phase 12 sites๐Ÿ“ Nanchang๐Ÿ“ Shanghai Rong Tao ยท Tests: KQ-2002 CAR-T cells ๏ผˆCD19/CD22 CAR T-Cells๏ผ‰ UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. NCT06927466Phase 18 sites๐Ÿ“ Beijing๐Ÿ“ Nanchang๐Ÿ“ Nanchang Shanghai Pharmaceutical Group Biological Therapy Technologyโ€ฆ ยท Tests: B019 CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol NCT05648019Phase 22 sites๐Ÿ“ Singapore๐Ÿ“ Singapore KK Women's and Children's Hospital ยท Tests: Anti-CD19 CAR T-cells Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL NCT06863259Phase 11 site๐Ÿ“ Cincinnati Children's Hospital Medical Center, Cincinnati ยท Tests: Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma NCT06961669NA1 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) NCT04150497Phase 1, Phase 219 sites๐Ÿ“ Los Angeles๐Ÿ“ Aurora๐Ÿ“ Denver Cellectis S.A. ยท Tests: UCART22, CLLS52 Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation NCT06339775Phase 41 site๐Ÿ“ Zhenzhou Suping ZHANG ยท Tests: Blinatumomab Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Shanghai Medolution Ltd. ยท Tests: Keynatinib CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors NCT06735495Phase 1, Phase 21 site๐Ÿ“ Wuhan Union Hospital, Tongji Medical College, Huazhong Universityโ€ฆ ยท Tests: CD19&CD22 bispecific CAR-T cells HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044Phase 1, Phase 233 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy